伊匹木单抗
 | |
| 单克隆抗体 | |
|---|---|
| 种类 | 完整抗体 |
| 目标 | CTLA-4 |
| 临床资料 | |
| 读音 | i pi lim′ ue mab |
| 商品名 | Yervoy |
| 其他名称 | BMS-734016,[1] MDX-010,[2] MDX-101 |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a611023 |
| 核准状况 | |
| 怀孕分级 |
|
| 给药途径 | 静脉注射 (IV) |
| ATC码 | |
| 法律规范状态 | |
| 法律规范 |
|
| 药物动力学数据 | |
| 生物半衰期 | 15 days[7] |
| 识别信息 | |
| CAS号 | 477202-00-9  |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| ChEMBL | |
| 化学信息 | |
| 化学式 | C6742H9972N1732O2004S40 |
| 摩尔质量 | 148,634.46 g·mol−1 |
伊匹木单抗（INN：ipilimumab）用于治疗黑色素瘤、肾癌、间皮瘤和非小细胞肺癌[8] [9]。常与纳武利尤单抗（INN：nivolumab）并用[9]。透过静脉缓慢注射[9]。
常见副作用包括皮疹、瘙痒、疲倦、腹泻、恶心、发烧、甲状腺问题、呼吸急促、肝炎和腹痛[9]。其他副作用包括可能发生肠道炎、毒性表皮坏死溶解症和周边神经病变[8]。它是一种单克隆抗体，可与CTLA-4结合并阻断它的功能，进而增强T细胞对抗癌的活性[9]。
伊匹木单抗于2011年在美国和欧洲取得医疗使用许可[9] [8]。
参考文献
[编辑]- ^ Yervoy, ipilimumab (BMS-734016) - Product Profile - BioCentury. BioCentury Online Intelligence. BioCentury Publications. [11 August 2016].
- ^ USAN. STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL - ipilimumab (新闻稿). American Medical Association (AMA). [2013-01-12]. （原始内容存档于2016-02-23）.
- ^ Regulatory Decision Summary for Yervoy. Drug and Health Products Portal. 7 December 2023 [2 April 2024].
- ^ Yervoy 5 mg/ml concentrate for solution for infusion - Summary of Product Characteristics (SmPC). (emc). 3 August 2020 [2 October 2020].
- ^ Yervoy- ipilimumab injection. DailyMed. 13 August 2020 [2 October 2020].
- ^ Yervoy EPAR. European Medicines Agency (EMA). 17 September 2018 [2 October 2020].
- ^ Ipilimumab: Uses, Interactions, Mechanism of Action. DrugBank Online. 25 March 2011 [18 September 2024].
- ^ 8.0 8.1 8.2 Ipilimumab Monograph for Professionals. Drugs.com. [28 November 2021]. （原始内容存档于6 May 2021） （英语）.
- ^ 9.0 9.1 9.2 9.3 9.4 9.5 Yervoy. [28 November 2021]. （原始内容存档于28 September 2020）.
外部链接
[编辑]- Ipilimumab. NCI Drug Dictionary. National Cancer Institute.
- Ipilimumab. National Cancer Institute. 21 April 2011.
